安旭生物收盘上涨2.08%，滚动市盈率30.77倍，总市值48.05亿元

Company Overview - Anxu Bio focuses on the research, development, production, and sales of POCT reagents and instruments [1] - The company has been recognized as a "Zhejiang Province Intellectual Property Demonstration Enterprise" and a "National Intellectual Property Advantage Enterprise" [1] - As of 2024, Anxu Bio has obtained a total of 305 authorized patents, including 43 invention patents [1] Financial Performance - For Q1 2025, Anxu Bio reported a revenue of 115 million yuan, a year-on-year decrease of 10.90% [1] - The net profit for the same period was approximately 34.03 million yuan, reflecting a year-on-year decline of 51.52% [1] - The gross profit margin for the company stood at 42.32% [1] Market Position - Anxu Bio's current price-to-earnings (PE) ratio is 30.77, compared to the industry average of 49.12 and the industry median of 36.07 [2] - The company's total market capitalization is 4.805 billion yuan [1][2] - As of Q1 2025, six institutions hold shares in Anxu Bio, with a total holding of approximately 50.38 million shares valued at 1.998 billion yuan [1]